THERAPEUTIC CLEARANCE OF COMPLEMENT C5A

Information

• Research Project
• 3498114

• ApplicationId

  3498114

• Core Project Number

  R43GM040797

• Full Project Number

  1R43GM040797-01

• Serial Number

  40797

• FOA Number

• Sub Project Id

• Project Start Date

  8/1/1988 - 36 years ago

• Project End Date

  1/31/1989 - 35 years ago

• Program Officer Name

• Budget Start Date

  8/1/1988 - 36 years ago

• Budget End Date

  1/31/1989 - 35 years ago

• Fiscal Year

  1988

• Support Year

  1

• Suffix

• Award Notice Date

  7/14/1988 - 36 years ago

Organizations

• SYNERGEN, INC.

The overall goal of the proposed research is to provide a specific, practical means for inactivating C5a in patients at risk of adult respiratory distress syndrome (ARDS). C5a is a key contributory, possibly necessary factor in the pathological course of ARDS. The proteins capable of inactivating C5a noted in the literature are poorly characterized. Synergen's scientists have selected one of these proteins to isolate from human tissue, then characterize its mode of action. An assay based on this biological activity will be used to purify, characterize, clone and express the protein by recombinant DNA technologies. By reducing the action of C5a in patients at risk for ARDS, we expect that the protein will provide a useful therapeutic agent for prevention or amelioration of the pathology.

IC Name

• Activity

  R43

• Administering IC

  GM

• Application Type

  1

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

• Sub Project Total Cost

• ARRA Funded

• CFDA Code

  821

• Ed Inst. Type

• Funding ICs

• Funding Mechanism

• Study Section

  SSS

• Study Section Name

• Organization Name

  SYNERGEN, INC.

• Organization Department

• Organization DUNS

• Organization City

  BOULDER

• Organization State

  CO

• Organization Country

  UNITED STATES

• Organization Zip Code

  80301

• Organization District

  UNITED STATES